Literature DB >> 19559761

Interaction of elongation factor 1-alpha with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro.

F Gillardon1.   

Abstract

Autosomal dominant mutations in leucine-rich repeat kinase 2 (LRRK2) are the most common genetic cause of late-onset Parkinson's disease. However, the regulators/effectors contributing to the (patho-)physiological functions of LRRK2 remain poorly defined. Here we show that human LRRK2 co-purifies/co-immunoprecipitates with elongation factor 1-alpha (EF1A). Co-incubation of recombinant LRRK2 and EF1A significantly reduces the kinase activity of LRRK2, whereas its GTPase activity remains unchanged. In addition to its canonical role in mRNA translation, EF1A maintains stability of the microtubule cytoskeleton. In the present study, EF1A promotes microtubule assembly in an in vitro tubulin polymerization assay which is impaired by co-incubation with LRRK2 at sub-stoichiometric concentrations. These findings suggest that the interaction between LRRK2 and EF1A may reciprocally modulate their physiological function.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19559761     DOI: 10.1016/j.neuroscience.2009.06.051

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  24 in total

1.  Purification, crystallization and preliminary X-ray crystallographic analysis of mammalian translation elongation factor eEF1A2.

Authors:  A Yaremchuk; V F Shalak; O V Novosylna; B S Negrutskii; T Crépin; A V El'skaya; M Tukalo
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2012-02-22

Review 2.  LRRK2 pathobiology in Parkinson's disease.

Authors:  Ian Martin; Jungwoo Wren Kim; Valina L Dawson; Ted M Dawson
Journal:  J Neurochem       Date:  2014-10-10       Impact factor: 5.372

Review 3.  LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

Authors:  A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Exp Neurol       Date:  2014-06-04       Impact factor: 5.330

Review 4.  Synaptic protein alterations in Parkinson's disease.

Authors:  Ilse S Pienaar; David Burn; Christopher Morris; David Dexter
Journal:  Mol Neurobiol       Date:  2011-12-29       Impact factor: 5.590

5.  Heterodimerization of Lrrk1-Lrrk2: Implications for LRRK2-associated Parkinson disease.

Authors:  Justus C Dachsel; Kenya Nishioka; Carles Vilariño-Güell; Sarah J Lincoln; Alexandra I Soto-Ortolaza; Jennifer Kachergus; Kelly M Hinkle; Michael G Heckman; Barbara Jasinska-Myga; Julie P Taylor; Dennis W Dickson; Rachel A Gibson; Faycal Hentati; Owen A Ross; Matthew J Farrer
Journal:  Mech Ageing Dev       Date:  2010-02-06       Impact factor: 5.432

6.  LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction.

Authors:  Seongsoo Lee; Hsin-Ping Liu; Wei-Yong Lin; Huifu Guo; Bingwei Lu
Journal:  J Neurosci       Date:  2010-12-15       Impact factor: 6.167

7.  ARHGEF7 (Beta-PIX) acts as guanine nucleotide exchange factor for leucine-rich repeat kinase 2.

Authors:  Karina Haebig; Christian Johannes Gloeckner; Marta Garcia Miralles; Frank Gillardon; Claudia Schulte; Olaf Riess; Marius Ueffing; Saskia Biskup; Michael Bonin
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

Review 8.  Cellular effects of LRRK2 mutations.

Authors:  Mark R Cookson
Journal:  Biochem Soc Trans       Date:  2012-10       Impact factor: 5.407

9.  Mutant LRRK2 enhances glutamatergic synapse activity and evokes excitotoxic dendrite degeneration.

Authors:  Edward D Plowey; Jon W Johnson; Erin Steer; Wan Zhu; David A Eisenberg; Natalie M Valentino; Yong-Jian Liu; Charleen T Chu
Journal:  Biochim Biophys Acta       Date:  2014-05-27

Review 10.  ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.

Authors:  Manish Verma; Erin K Steer; Charleen T Chu
Journal:  Biochim Biophys Acta       Date:  2013-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.